Blood-Based Disease Assessment in SCLC: A Perpetual Proof of Concept or a Clinically Important Tool?

J Thorac Oncol. 2020 Feb;15(2):163-165. doi: 10.1016/j.jtho.2019.11.012.

Authors

Jacob M Sands¹, Marina S D Milan², Geoffrey R Oxnard²

Affiliations

¹ Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: jacob_sands@dfci.harvard.edu.
² Dana-Farber Cancer Institute, Boston, Massachusetts.

PMID: 32127182
DOI: 10.1016/j.jtho.2019.11.012

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Small Cell*
Cell-Free Nucleic Acids*
DNA
Humans
Lung Neoplasms*

Substances

Cell-Free Nucleic Acids
DNA